Next Article in Journal
Therapeutic Potential of Luteolin on Impaired Wound Healing in Streptozotocin-Induced Rats
Next Article in Special Issue
Comparing Patient Characteristics, Clinical Outcomes, and Biomarkers of Severe Asthma Patients in Taiwan
Previous Article in Journal
The Neuroinflammatory Role of Pericytes in Epilepsy
Previous Article in Special Issue
Leukotriene B4 Receptors Are Necessary for the Stimulation of NLRP3 Inflammasome and IL-1β Synthesis in Neutrophil-Dominant Asthmatic Airway Inflammation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 9
Issue 7
10.3390/biomedicines9070760
Review Report
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Biologic Therapy and Severe Asthma in Children

Biomedicines 2021, 9(7), 760; https://doi.org/10.3390/biomedicines9070760
by Daniele Russo 1,2, Paola Di Filippo 1,2,*, Marina Attanasi 1,2, Mauro Lizzi 1,2, Sabrina Di Pillo 1,2 and Francesco Chiarelli 1
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Biomedicines 2021, 9(7), 760; https://doi.org/10.3390/biomedicines9070760
Submission received: 15 June 2021 / Revised: 23 June 2021 / Accepted: 24 June 2021 / Published: 30 June 2021
(This article belongs to the Special Issue Molecular Targets for Biological Therapies of Severe Asthma)

Round 1

Reviewer 1 Report

Biomedicines

Manuscript ID: 1281065

Type of manuscript: Review

Title: Biologic Therapy in Pediatric Severe Asthma

The Authors present an up-to-date review of the data on the currently available biologic therapies in pediatric severe asthma, including their safety and efficacy. The paper is interesting for physicians interested in this field as it is supported by updated list of related studies. It was a very good idea to include the flowchart - Fig. 2 showing recommendations how to select the best treatment for severe asthma in children in clinical practice.

Generally, this is very good and exhaustive review of the current knowledge in this field, nicely written and in good English, which I recommend for publication in the present from.

Author Response

Thank you very much for your comment.

 

Reviewer 2 Report

In this review, Russo and collaborators perform an extensively and detailed overview of the different biological treatment for childhood severe asthma. The article is well structured and provided sufficient and detailed information about this topic. They describe in depth anti-IL5 therapies and others such as omalizumab (anti-IgE), tezepelumab (anti TSLP) and dupilumab (anti-IL-4/IL-13). I only have several minor comments:

  1. Table 1: Please, provide the head for each column (i.e.: Biological drug, Target molecule, etc.). Also you must add a new column with the references for each treatment.
  2. Figure 1 must be place before in text (just before section 3, Line 142).
  3. Lines 268-269: “Benralizumab is the most recent monoclonal anti IL–5 antibody authorized for the human subjects” is not quite correct. Benralizumab is not anti-IL-5 antibody, is anti-IL-5Rα antibody. Please, reformulate this sentence.

Author Response

We thank the reviewer for his/her relevant comments.

  1. We provided the head of the table and we added a new column with the references.
  2. We placed figure 3 before section 3, as suggested
  3. We reformulated the sentence, as suggested
Back to TopTop